Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina
Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...
Circode Bio
Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular‑RNA (circRNA) therapeutic HM2003 Injection...
CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials
China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...
BMS Taps into Circular RNA Potential with Shanghai Circode Bio Agreement
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant...
Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential
Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...